ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access for CC-10004

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03740516
Expanded Access Status : Available
First Posted : November 14, 2018
Last Update Posted : November 14, 2018
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-10004.

Condition or disease Intervention/treatment
Bechet's Disease Drug: CC-10004

Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access for CC-10004

Resource links provided by the National Library of Medicine

Drug Information available for: Apremilast


Intervention Details:
  • Drug: CC-10004
    CC-10004 will be administered orally
    Other Name: Apremilast, Otezla

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03740516


Contacts
Contact: Celgene Medical Information 1-888-771-0141 medinfo@celgene.com

Locations
United States, New Jersey
Celgene
Summit, New Jersey, United States, 07901
Sponsors and Collaborators
Celgene

Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT03740516     History of Changes
Other Study ID Numbers: CC-10004
First Posted: November 14, 2018    Key Record Dates
Last Update Posted: November 14, 2018
Last Verified: November 2018

Keywords provided by Celgene:
Expanded Access
Compassionate Use

Additional relevant MeSH terms:
Apremilast
Thalidomide
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Immunosuppressive Agents
Immunologic Factors
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents